PVRIG (GSK-4381562 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is a research-grade biosimilar to GSK-4381562, designed to target PVRIG (PVR-related immunoglobulin domain-containing protein), also known as CD112R. PVRIG functions as an inhibitory immune checkpoint receptor expressed on T cells and NK cells that binds to its ligand PVRL2 (CD112), delivering suppressive signals that dampen anti-tumor immune responses. By engaging PVRL2, PVRIG inhibits T cell activation and cytotoxic function, contributing to immune evasion mechanisms exploited by tumors. PVRIG is particularly relevant in cancer immunology research, where it represents an emerging therapeutic target for overcoming resistance to existing checkpoint inhibitors.

GSK-4381562 is a clinical-stage antibody developed to block the PVRIG-PVRL2 interaction, thereby enhancing T cell-mediated anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating PVRIG biology, studying immune checkpoint mechanisms, and exploring combination immunotherapy strategies in preclinical models. It enables examination of PVRIG's role in tumor microenvironments and its potential as a therapeutic target across various malignancies.